July 13, 2017
1 min read
Save

Five-year sacroiliac joint radiographic progression found to be limited in patients with axial SpA

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Among patients with axial spondyloarthritis, five-year sacroiliac joint radiographic progression was limited, according to a recently published study.

“The main findings of this 5-year follow-up study can be summarized as follows: 5-year radiographic [sacroiliac joint] SIJ progression is statistically significant but of limited magnitude; strategically chosen definitions of radiographic progression may be more sensitive to change over time than the rigid (binary) [modified New York] mNY-based definition; and inflammation on MRI-SIJ is highly predictive of a structural radiographic SIJ progression,” Maxime Dougados, MD, from Paris Descartes University, and colleagues wrote. “Moreover, these data provide meaningful information for the clinician who likes to determine the risk of progression in an individual patient, using baseline parameters such as [human leukocyte antigen B-27] HLA-B27 positivity, radiographic structural damage, MRI-SIJ inflammation and abnormal [C-reactive protein] CRP.”

Researchers assessed sacroiliac joint radiographic progression and MRI-SIJ at 2 years and 5 years in 416 patients with axial spondyloarthritis. They defined progression as either the change from non-radiographic to radiographic sacroiliitis by mNY criteria, a change of at least one grade or a change of at least one grade except for the change from 0 to 1.

They found net progression occurred for the first definition of progression in 5.1% of patients compared with 13% for the second definition and 10.3% for the third definition. In addition, baseline MRI-SIJ was linked with structural damage after 5 years in HLA-B27 positive patients (odds ratio = 5.39), as well as HLA-B27 negative patients (odds ratio = 2.16). – by Will A. Offit

Disclosure: The researchers report no relevant financial disclosures.